Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan’s Kirin, Kyowa Merge To Strengthen Biotechnology Focus

This article was originally published in The Pink Sheet Daily

Executive Summary

Kirin will acquire a 50.1 percent stake in Kyowa Hakko in a deal valued at close to ¥300 billion ($2.64 billion).

You may also be interested in...



ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal

Agreement with Japanese firm to develop and commercialize Phase I c-Met inhibitor ARQ 197 in Asia provides much-needed cash infusion.

Schering-Plough/Aveo Will Develop Novel Cancer Biologic Based On Biomarkers

Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million

Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel